Longevity Biotech is developing a new class of therapeutic candidates called Hybridtides®. Our focus is on delivering clinically transformative products that tackle the most challenging aspects of medicine today. The unique Hybridtide® scaffold provides critical enhancements over previous peptide development efforts.

Longevity Biotech has assembled a team of worldwide experts in leading peptide drug development programs. Our growing management team along with our advisors have deep and broad expertise in bringing new biological products into and through clinical trials.